Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.200
-14.800-3.04%
Volume:349.28K
Turnover:164.29M
Market Cap:112.86B
PE:-285.00
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.70
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.07
PE(LYR):-285.00
PS:46.24

Loading ...

Stock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks

Stock Track
·
Jun 01

June Investment Strategy and Top Ten Stock Picks for Hong Kong Stocks

Stock News
·
Jun 01

Kelun-Biotech says Phase III study shows sac-TMT plus Keytruda extends PFS in first-line PD-L1+ NSCLC

Reuters
·
May 30

Kelun-Biotech says China regulator accepts NDA for lunbotinib in RET fusion-positive NSCLC

Reuters
·
May 30

Stock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally

Stock Track
·
May 28

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 3.21% in Regular Trading, Profit-Taking Triggered by Widening Net Losses Despite Prior Rally on Clinical Data

Market Focus
·
May 28

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 3.07% in Regular Trading, Nomura Raises Target Price to HK$544.42 on Encouraging Phase III ADC Data

Market Focus
·
May 27

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 3.12% in Regular Trading, ASCO Annual Meeting Data Continues to Catalyze Pipeline Value Reassessment

Market Focus
·
May 26

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

MT Newswires Live
·
May 22

SKB BIO Receives "Buy" Rating from China Post Securities on Anticipated Global Pipeline Value Realization

Stock News
·
May 22

BUZZ-Sichuan Kelun-Biotech at 4-week high on positive lung cancer trial with Merck

Reuters
·
May 22

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 7.58% in Regular Trading, ASCO Oral Presentations and Phase III Lung Cancer Trial Success Drive Momentum

Market Focus
·
May 22

Stock Track | SKB BIO Soars 5.16% at Open on Positive Phase III Lung Cancer Data and ASCO Presentation News

Stock Track
·
May 22

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 5.34% at Open, ASCO Oral Presentations and Multiple Phase III Successes Drive Momentum

Market Focus
·
May 22

SKB BIO Highlights Robust Sac-TMT Phase III and Lunbotinib Phase II Data Ahead of ASCO 2026

Bulletin Express
·
May 22

SKB BIO (06990) to Present Multiple Innovative Drug Research Findings at 2026 ASCO Annual Meeting

Stock News
·
May 22

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Nda for Lunbotinib Fumarate Accepted for Review by Nmpa

THOMSON REUTERS
·
May 22

BRIEF-Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial

Reuters
·
May 22

Sichuan Kelun-Biotech Biopharmaceutical: Sacituzumab Tirumotecan + Pembrolizumab Extended Pfs VS Pembrolizumab Alone in Phase 3 Lung Cancer Trial

THOMSON REUTERS
·
May 22

Sichuan Kelun-Biotech Biopharmaceutical-Safety Profile of Sac-TMT + Pembrolizumab Generally Manageable, Consistent With Safety Profile of Components

THOMSON REUTERS
·
May 22